FindMyKOL
Clinical trialNCT01785056UnknownInterventional

IVIG Treatment in Systemic Sclerosis

NCT01785056 is an interventional trial sponsored by Georgetown University. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies Immunoglobulin G in Diffuse Scleroderma and Systemic Sclerosis. The registry lists an enrollment of 14 participants at 2 sites in 1 country. The registry lists a start date of 30 Apr 2013 and a primary completion date of 31 Jan 2018.

SponsorGeorgetown University →Enrollment14Diffuse SclerodermaSystemic Sclerosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01785056
FieldValue
Registry IDNCT01785056
StatusUnknown
Study typeInterventional trial
Lead sponsorGeorgetown University
Enrollment14
Registered sites2
Countries1
ConditionsDiffuse Scleroderma and Systemic Sclerosis
DrugsImmunoglobulin G
Start30 Apr 2013
Primary completion31 Jan 2018
Study completion31 Jan 2019
Last update posted17 Jul 2018

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research is to study the effects of Privigen (intravenous immunoglobulin) on the skin in patients with scleroderma. Approximately 24 subjects will take part in this investigator-initiated study at Georgetown University Hospital and Johns Hopkins Hospital. This study will last for one year (12 months). This research is being done because systemic sclerosis can cause severe, progressive organ involvement. The investigators hope this study treatment will improve the outcomes in this disease, including skin, muscle, joint, gastrointestinal, and lung involvement.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

District of Columbia, United States1 site
  • Georgetown University Hospital

    Washington D.C.

Maryland, United States1 site
  • Johns Hopkins Hospital

    Baltimore

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of Columbia: 1 siteDC1
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01785056

Each answer restates registry values shown on this page.

What is NCT01785056?

NCT01785056 is an interventional trial sponsored by Georgetown University. It studies Immunoglobulin G in Diffuse Scleroderma and Systemic Sclerosis.

Who leads NCT01785056?

The registry names Virginia D Steen, MD (principal investigator, Georgetown University Hospital) as the overall official.

Where does NCT01785056 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01785056 study?

The registered drug and biological interventions are Immunoglobulin G.

When is NCT01785056 expected to complete?

The registry lists a primary completion date of 31 Jan 2018 and a study completion date of 31 Jan 2019. The sponsor last updated the record on 17 Jul 2018.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.